Healthcare · Biotechnology
Price
$1.49
Market Cap
$61.3M
Employees
40
Beta
0.43
Avg Volume
19,955
CEO
Lan Huang
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Runs with full report
Price Overview
Last updated: Jul 10, 2026 4:14am (just now)
Current data · timestamped when a report runs
$1.49
Change · Jul 10
-0.18 (-10.78%)
Day Range
$1.47 – $1.68
52-Week Range
$1.18 – $2.44
50-Day MA
$1.60
200-Day MA
$1.70
Volume
71,631.00
Share Structure
Outstanding
41,119,820.00
Float
31,950,100.00
Free Float
77.7%
Normal free float
— 77.7% of shares trade freely, ~22.3% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-7.45
Stock Price: $1.49
EPS (Diluted): -0.20
EPS (Diluted): -0.20
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-2.05
Stock Price: $1.49
Total Equity: -$32.16M
Shares: 40,406,347
Total Equity: -$32.16M
Shares: 40,406,347
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-7.17
Market Cap: $61.27M
Total Debt: $0.00
Cash: $7.79M
EBITDA: -$8.54M
Total Debt: $0.00
Cash: $7.79M
EBITDA: -$8.54M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$58.4M
Market Cap: $61.27M
Total Debt: $0.00
Cash: $7.79M
Total Debt: $0.00
Cash: $7.79M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $1.49
Revenue: $0.00
Shares: 40,406,347
Revenue: $0.00
Shares: 40,406,347
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$87,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$8.95M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$7.99M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
23.8%
Net Income: -$7.99M
Total Equity: -$32.16M
Total Equity: -$32.16M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-136.4%
Operating Income: -$8.95M
Tax Rate: -1.0%
Equity: -$32.16M
Total Debt: $0.00
Cash: $7.79M
Tax Rate: -1.0%
Equity: -$32.16M
Total Debt: $0.00
Cash: $7.79M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.54
Current Assets: $20.88M
Current Liabilities: $13.58M
Current Liabilities: $13.58M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$32.16M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$32.16M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 40,406,347
Shares: 40,406,347
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-0.80
Total Equity: -$32.16M
Shares: 40,406,347
Shares: 40,406,347
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.50
Operating CF: -$20.02M
CapEx: -$50,000
Shares: 40,406,347
CapEx: -$50,000
Shares: 40,406,347
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.49
Stock Price: $1.49
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$7.99M
Net Income: -$7.99M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares BYSI against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 10, 2026 3:07am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $1.4M | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $302,000 | $0 | $87,000 |
| Gross Profit | $1.4M | $1.4M | $-302,000 | $0 | $-87,000 |
| Operating Expenses | $67.6M | $38.6M | $14.8M | $8.8M | $8.9M |
| Operating Income | -$66.2M | -$37.2M | -$15.1M | -$8.8M | -$8.9M |
| Net Income | -$64.2M | -$33.3M | -$21.0M | -$11.1M | -$8.0M |
| EBITDA | -$64.5M | -$35.0M | -$13.6M | -$8.5M | -$8.5M |
| EPS | $-1.64 | $-0.85 | $-0.54 | $-0.28 | $-0.20 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 10, 2026 3:07am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $41.6M | $34.4M | $15.3M | $2.9M | $7.8M |
| Total Current Assets | $75.1M | $38.5M | $18.4M | $28.6M | $20.9M |
| Total Assets | $81.6M | $46.2M | $24.8M | $34.3M | $25.9M |
| Current Liabilities | $15.2M | $7.4M | $8.0M | $11.0M | $13.6M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $60.7M | $49.2M | $48.3M | $48.6M | $49.9M |
| Total Equity | $26.7M | -$6.0M | -$26.8M | -$32.9M | -$32.2M |
| Retained Earnings | -$342.0M | -$375.3M | -$396.3M | -$407.4M | -$408.4M |
Cash Flow (Annual)
Last updated: Jul 10, 2026 3:07am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$47.2M | -$28.2M | -$16.5M | -$16.4M | -$20.0M |
| Capital Expenditure | -$2.8M | $-34,000 | $-100,000 | $-224,000 | $-50,000 |
| Free Cash Flow | -$50.1M | -$28.2M | -$16.6M | -$16.7M | -$20.1M |
| Acquisitions (net) | $20.4M | $0 | $0 | $0 | $10.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$67.9M | -$7.2M | -$16.6M | -$1.7M | $4.9M |
Analyst Estimates (Annual)
Last updated: Jul 10, 2026 3:07am (1h ago)| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue |
$1.4M $1.4M – $1.4M
|
$83.7M $83.7M – $83.7M
|
$137.9M $137.9M – $137.9M
|
$194.6M $194.6M – $194.6M
|
| EBITDA |
$-270,199 $-270,199 – $-270,199
|
$16.7M $16.7M – $16.7M
|
$27.6M $27.6M – $27.6M
|
$38.9M $38.9M – $38.9M
|
| Net Income |
-$18.7M -$18.7M – -$18.7M
|
$10.1M $10.1M – $10.1M
|
$44.4M $44.4M – $44.4M
|
$80.0M $80.0M – $80.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 10, 2026 3:07am (1h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +0.0% | -100.0% | — | — |
| Gross Profit Growth | +0.0% | -122.4% | +100.0% | — |
| Operating Income Growth | +43.8% | +59.5% | +42.0% | -2.2% |
| Net Income Growth | +48.1% | +36.8% | +47.1% | +28.1% |
| EBITDA Growth | +45.8% | +61.0% | +37.7% | -0.6% |
Insider Trading (Recent)
Last updated: Jul 10, 2026 3:07am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Majeti Jiangwen | A-Award | 100,000.00 | $1.75 | $175,000 |
| 2026-07-01 | Qiu Min | A-Award | 100,000.00 | $1.75 | $175,000 |
| 2026-07-01 | Qiu Min | 0.00 | $0.00 | $0 | |
| 2026-07-01 | Li Na (NL) | 0.00 | $0.00 | $0 | |
| 2026-03-20 | Huang Lan | G-Gift | 260,582.00 | $0.00 | $0 |
| 2026-04-01 | Kirkby Matthew | A-Award | 23,902.00 | $1.64 | $39,199 |
| 2026-04-01 | Fabbio Patrick | A-Award | 22,165.00 | $1.64 | $36,351 |
| 2026-04-01 | Delaney Brendan | A-Award | 20,427.00 | $1.64 | $33,500 |
| 2026-04-01 | Majeti Jiangwen | A-Award | 21,730.00 | $1.64 | $35,637 |
| 2026-04-01 | Lu Yingjuan June | A-Award | 17,840.00 | $1.64 | $29,258 |
| 2026-04-01 | Huang Lan | A-Award | 11,514.00 | $1.80 | $20,771 |
| 2026-04-01 | Xu Sihai | A-Award | 18,689.00 | $1.64 | $30,650 |
| 2025-10-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | S-Sale | 85,798.00 | $1.72 | $147,573 |
| 2025-10-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | S-Sale | 45,513.00 | $1.76 | $80,103 |
| 2025-10-13 | Decheng Capital China Life Sciences USD Fund III, L.P. | S-Sale | 107,361.00 | $1.70 | $182,514 |
| 2025-10-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | S-Sale | 28,495.00 | $1.65 | $47,017 |
| 2025-10-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | S-Sale | 17,960.00 | $1.65 | $29,634 |
| 2025-10-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | S-Sale | 7,507.00 | $1.77 | $13,287 |
| 2025-10-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | S-Sale | 3,979.00 | $1.81 | $7,202 |
| 2025-10-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | S-Sale | 2,390.00 | $1.77 | $4,230 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for BYSI — it's generated by the pipeline (
market-narrative step).
No community reviews yet for BYSI.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.397 · fd27f02b · 2026-07-09 18:28:55